Next Generation Sequencing of  human BRAF melanoma cell lines treated with vemurafenib for 20 days
Purpose: The goals of this study are to compare NGS-derived transciptomes from human melanoma cell lines before and after vemurafenib in order to compare to a mouse model of melanoma using doxycycline that permits control of mutant BRAF expression. Treatment with doxycycline leads to loss of mutant BRAF expression and tumor regression, but tumors reoccur after a prolonged period of dormancy. Results: We found conserved expression changes in histone methyltransferase genes (HMT), including Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit (EZH2), Suppressor Of Variegation 3-9 Homolog 1(SUV39H1), Suppressor Of Variegation 3-9 Homolog 2 (SUV39H2), ASH2 Like, Histone Lysine Methyltransferase Complex Subunit (ASH2L), SET And MYND Domain Containing 2 (SYMD2), and Protein arginine methyltransferase 5 (PRMT5) and histone deacetylases (HDACs) HDACS 7, 9,10, and 11. Overall design: human melanoma mRNA profiles before and afer 20 days of exposure to vemurafnib